drugset / Trial / NCT00648323

Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

NCT00648323

Phase 4 Completed 80 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.

Timeline

Start
2003-11
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxazosin Small molecule 4 mg
Subject Doxazosin Small molecule 8 mg

Indications